BioSig Completes Enrollment in the PURE EP 2.0 Clinical Study

• 51 patients undergoing elective cardiac ablation treatments were enrolled in the trial at Mayo Clinic, Massachusetts General Hospital, and St. David’s Medical Center

• The trial is designed to demonstrate the quality and clinical value of the PURE EP^™ signals when compared to conventional sources of cardiac signals. The Company expects to announce the study results in Q3 2021

BioSig Technologies, Inc., a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced it completed enrollment in the PURE EP 2.0 clinical trial.

The multi-center, prospective clinical trial was conducted at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, TX, Mayo Clinic Florida Campus in Jacksonville, FL, and Massachusetts General Hospital in Boston, MA. During the trial, the PURE EP^™ System was used in all types of arrhythmia cases, including atrial fibrillation, ventricular tachycardia, and atrial flutter. Atrial fibrillation, the most common arrhythmia type affecting over 6 million people in the U.S.¹,  accounted for over 40% of enrollments.

The PURE EP^™ System has been awarded FDA 510(k) clearance. The Company commenced commercialization in 2020, having recently announced commercial sales to St. David’s HealthCare of Austin, Texas, an HCA Healthcare-owned hospital, and Mayo Foundation for Medical Education and Research. Clinical data, collected under the terms of the PURE EP 2.0 study, will support the national rollout to medical centers across the U.S.

The study aimed to establish the safe and effective use of the PURE EP^™ System and assess the quality of the PURE EP^™ intracardiac signals when compared to existing recording and mapping systems. Collected clinical data underwent randomized, blinded, controlled evaluation by a panel of independent electrophysiologists to determine the clinical value of the PURE EP^™ signals. The Company has submitted a scientific abstract for consideration by the Heart Rhythm Society. It expects to announce the study results at the Heart Rhythm 2021 convention, which is due to take place on July 28-31, 2021. The Company expects to publish the full clinical study results in leading industry publications in the second half of 2021.

In Q3 2020, the Company announced the data results recorded during 15 atrial fibrillation ablation procedures from the PURE EP^TM System, the signal recording system, and the 3D mapping system. The review concluded that the PURE EP^™ signals were preferred to conventional sources of intracardiac signals.

In addition to the enrolled patient data, the Company maintains a registry of over 600 ablation procedures performed with the PURE EP^™ System at eight hospitals in the United States. This dataset is being used to support new product development to complement the PURE EP^™ System.

"We are pleased to complete the enrollment in our flagship clinical study. The objective of our clinical strategy is to determine the clinical and economic benefits of the PURE EP^™ System which could include improved procedure efficacy, reduced procedure times, and a decrease in repeat procedures,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. “Strong clinical evidence is the foundation of our commercial strategy. We look forward to revealing the clinical findings from our trial in the coming months and engaging the healthcare community in our new, targeted studies to demonstrate the additional clinical value of our technology.”

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP^™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.